<DOC>
	<DOCNO>NCT00002107</DOCNO>
	<brief_summary>To determine MTD dose-limiting toxicity recombinant interleukin-2 ( aldesleukin ; Proleukin ) administer subcutaneously HIV-seropositive patient . To identify tolerable subcutaneous regimen replicate immunologic improvement demonstrate outpatient polyethylene glycolated IL-2 high-dose continuous infusion IL-2 study . To evaluate incidence level anti-IL-2 antibody formation subcutaneously administer Proleukin patient population .</brief_summary>
	<brief_title>A Phase I Study Subcutaneously Administered Proleukin ( Aldesleukin ) HIV-Infected Patients</brief_title>
	<detailed_description>Patients receive subcutaneous Proleukin , MTD determine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection ELISA Western blot . CD4 count &gt; 200 cells/mm3 . Required : FDAapproved antiretroviral therapy least 2 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1995</verification_date>
	<keyword>Interleukin-2</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>